Vir Biotechnology (VIR) Tax Provisions (2018 - 2026)
Vir Biotechnology recorded quarterly Tax Provisions of $170000.0 in Q1 2026, up 224.09% quarter-over-quarter from -$137000.0 in Q4 2025, and up 962.5% year-over-year from $16000.0 in Q1 2025.
Vir Biotechnology's Tax Provisions history runs 9 years deep, the most recent figure standing at $170000.0 for Q1 2026.
- In Q1 2026, Tax Provisions rose 962.5% year-over-year to $170000.0; the TTM figure through Mar 2026 stood at $371000.0 (up 126.41% YoY), while the FY2025 annual figure was $217000.0, up 118.95% from the prior year.
- Tax Provisions came in at $170000.0 for Q1 2026 at Vir Biotechnology, up from -$137000.0 in the prior quarter.
- In the past five years, Tax Provisions ranged from a high of $403.3 million in Q1 2022 to a low of -$157.2 million in Q2 2022.
- A 5-year average of $13.2 million and a median of -$86000.0 in 2024 frame the typical range for Tax Provisions.
- On a YoY basis, Tax Provisions climbed as much as 205658.16% in 2022 and fell as far as 296756.6% in 2022.
- Vir Biotechnology's Tax Provisions stood at -$50.0 million in 2022, then surged by 90.44% to -$4.8 million in 2023, then jumped by 98.2% to -$86000.0 in 2024, then plunged by 59.3% to -$137000.0 in 2025, then jumped by 224.09% to $170000.0 in 2026.
- According to Business Quant data, Tax Provisions over the past three periods registered $170000.0, -$137000.0, and $168000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -11.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -859,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 221.50 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 216,000.00 |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 104.00 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 15.66 Mn |
| 10 | Vir Biotechnology | 1.33 Bn | 1.33 Bn | - | 170,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 170,000.00 |
| Dec 31, 2025 | -137,000.00 |
| Sep 30, 2025 | 168,000.00 |
| Jun 30, 2025 | 170,000.00 |
| Mar 31, 2025 | 16,000.00 |
| Dec 31, 2024 | -86,000.00 |
| Sep 30, 2024 | 177,000.00 |
| Jun 30, 2024 | -1.51 Mn |
| Mar 31, 2024 | 276,000.00 |
| Dec 31, 2023 | -4.78 Mn |
| Sep 30, 2023 | -3.21 Mn |
| Jun 30, 2023 | -2.85 Mn |
| Mar 31, 2023 | -2.23 Mn |
| Dec 31, 2022 | -50.04 Mn |
| Sep 30, 2022 | 42.42 Mn |
| Jun 30, 2022 | -157.23 Mn |
| Mar 31, 2022 | 403.29 Mn |
| Dec 31, 2021 | 20.64 Mn |
| Sep 30, 2021 | 334,000.00 |
| Jun 30, 2021 | 53,000.00 |
| Mar 31, 2021 | 196,000.00 |
| Dec 31, 2020 | -30,000.00 |
| Sep 30, 2020 | 22,000.00 |
| Jun 30, 2020 | 46,000.00 |
| Mar 31, 2020 | 16,000.00 |
| Dec 31, 2019 | 149,000.00 |
| Sep 30, 2019 | -13,000.00 |
| Jun 30, 2019 | 19,000.00 |
| Dec 31, 2018 | 20,000.00 |